<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00318071</url>
  </required_header>
  <id_info>
    <org_study_id>INT-LR-001</org_study_id>
    <nct_id>NCT00318071</nct_id>
  </id_info>
  <brief_title>Multi MERCI (Mechanical Embolus Removal in Cerebral Ischemia [MERCI™])</brief_title>
  <acronym>Multi-MERCI</acronym>
  <official_title>A Multinational Controlled Registry to Evaluate the Concentric Merci Retriever System (Mechanical Embolus Removal in Cerebral Ischemia [MERCI™])</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stryker Neurovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stryker Neurovascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of the Multi MERCI trial were:&#xD;
&#xD;
        -  to evaluate the addition of the Merci L5 Retriever&#xD;
&#xD;
        -  additionally permit use of the Merci Retrieval System in the setting of persistent clot&#xD;
           following IV t-PA treatment (use in the 0-8 hour window for patients ineligible for IV&#xD;
           t-PA was also permitted)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Per the Multi MERCI protocol, up to 230 patients could be treated at up to 30 centers.&#xD;
&#xD;
      The intended trial indication for the Merci L5 Retriever was to restore blood flow in the&#xD;
      neurovasculature by removing thrombus in patients experiencing ischemic stroke. Patients that&#xD;
      were contraindicated or failed treatment with intravenous t-PA were allowed to be enrolled&#xD;
      under the Multi MERCI protocol.&#xD;
&#xD;
      Per the Multi MERCI protocol, following inclusion of the Merci L5 Retriever the operating&#xD;
      physician was required to initiate treatment with the Merci L5 Retriever. At the physician's&#xD;
      discretion, subsequent passes could be made with the Merci L5 Retriever, Merci X6 Retriever&#xD;
      and/or Merci X5 Retriever.&#xD;
&#xD;
      Adverse events were adjudicated by an independent Data Safety and Monitoring Board (Capital&#xD;
      DSMB).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Revascularization success; Rates of device-related serious adverse events</measure>
    <time_frame>post-procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>modified Rankin scores</measure>
    <time_frame>90-day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>90-day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic hemorrhage rate</measure>
    <time_frame>24 hour post procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">164</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment arm patients had at least one Merci Retriever deployed</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Merci Retriever</intervention_name>
    <description>For patients eligible to participate in the trial, the operating physician initiated treatment with the Merci L5 Retriever to remove large vessel thrombotic occlusion and recanalization of the vessel. Subsequent treatment could be made with Merci X6 or X5 Merci Retrievers.&#xD;
Large vessel arteries are defined as internal carotid, middle cerebral M1/M2 segments, basilar, and vertebral arteries.&#xD;
Recanalization was defined as TIMI II or TIMI III per angiography.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Angiographically confirmed large vessel ischemic stroke (occlusion may include the&#xD;
             following: internal carotid artery (ICA), M1/M2, vertebral, or basilar arteries)&#xD;
&#xD;
          -  Intervention is able to be performed within 8 hours of symptom onset&#xD;
&#xD;
          -  Patients &gt; 18 years of age&#xD;
&#xD;
          -  NIHSS score 8+&#xD;
&#xD;
          -  Failed IV t-PA treatment or contraindicated for IV t-PA&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  International Normalized Ratio (INR) &gt; 3.0&#xD;
&#xD;
          -  Platelet count &lt; 30,000&#xD;
&#xD;
          -  Heparin use in previous 24 hours with PTT &gt; 2X normal&#xD;
&#xD;
          -  Baseline bloog glucose &lt; 50 mg/dL&#xD;
&#xD;
          -  Baseline computed tomography (CT) showing mass effect with midline shift&#xD;
&#xD;
          -  Severe sustained hypertension (SBP &gt; 185 or DBP &gt; 110) that cannot be controlled with&#xD;
             medication&#xD;
&#xD;
          -  Patient is pregnant, has anticipated life expectancy &lt; 3 months, or has severe allergy&#xD;
             to contrast medium&#xD;
&#xD;
          -  Arterial stenosis &gt; 50% proximal to embolus&#xD;
&#xD;
          -  Excessive arterial tortuosity that precludes the study device from reaching the target&#xD;
             area&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wade S Smith, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.concentric-medical.com</url>
    <description>Concentric Medical Website</description>
  </link>
  <results_reference>
    <citation>Smith WS, Sung G, Saver J, Budzik R, Duckwiler G, Liebeskind DS, Lutsep HL, Rymer MM, Higashida RT, Starkman S, Gobin YP; Multi MERCI Investigators, Frei D, Grobelny T, Hellinger F, Huddle D, Kidwell C, Koroshetz W, Marks M, Nesbit G, Silverman IE. Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke. 2008 Apr;39(4):1205-12. doi: 10.1161/STROKEAHA.107.497115. Epub 2008 Feb 28.</citation>
    <PMID>18309168</PMID>
  </results_reference>
  <results_reference>
    <citation>Smith WS. Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke. Results of the multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, part I. AJNR Am J Neuroradiol. 2006 Jun-Jul;27(6):1177-82.</citation>
    <PMID>16775259</PMID>
  </results_reference>
  <results_reference>
    <citation>Flint AC, Duckwiler GR, Budzik RF, Liebeskind DS, Smith WS; MERCI and Multi MERCI Writing Committee. Mechanical thrombectomy of intracranial internal carotid occlusion: pooled results of the MERCI and Multi MERCI Part I trials. Stroke. 2007 Apr;38(4):1274-80. Epub 2007 Mar 1.</citation>
    <PMID>17332445</PMID>
  </results_reference>
  <results_reference>
    <citation>Lutsep HL, Rymer MM, Nesbit GM. Vertebrobasilar revascularization rates and outcomes in the MERCI and multi-MERCI trials. J Stroke Cerebrovasc Dis. 2008 Mar-Apr;17(2):55-7. doi: 10.1016/j.jstrokecerebrovasdis.2007.11.003.</citation>
    <PMID>18346645</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>July 14, 2005</study_first_submitted>
  <study_first_submitted_qc>April 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2006</study_first_posted>
  <last_update_submitted>November 6, 2014</last_update_submitted>
  <last_update_submitted_qc>November 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Ischemic</keyword>
  <keyword>Thrombus</keyword>
  <keyword>Embolectomy</keyword>
  <keyword>Thrombectomy</keyword>
  <keyword>Merci</keyword>
  <keyword>Concentric</keyword>
  <keyword>Embolus</keyword>
  <keyword>Embolism</keyword>
  <keyword>Mechanical</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

